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1. INTRODUCTION {#cas14248-sec-0001}
===============

Colorectal cancer (CRC) is a leading cause of tumor‐associated morbidity and mortality worldwide, and its incidence continues to rise.[1](#cas14248-bib-0001){ref-type="ref"}, [2](#cas14248-bib-0002){ref-type="ref"} Despite recent advances in therapeutic approaches, including chemotherapy and molecular targeted therapy, relapse is frequently found among patients with CRC, particularly for those with advanced disease.[3](#cas14248-bib-0003){ref-type="ref"}

Intratumor heterogeneity (ITH), defined as molecular and cellular heterogeneity within a single tumor, is thought to cause the development of resistance against chemotherapy and leads to therapeutic failure because the presence of distinct subpopulations of cells with different sensitivities to chemotherapeutic drugs increases the risk of resistance and recurrence.[4](#cas14248-bib-0004){ref-type="ref"} Therefore, identification of oncogenes expressed in all tumor cells within a single tumor is essential for the discovery of promising therapeutic targets despite ITH.

Amplification of chromosome 7 is frequently found in CRC and colorectal adenoma tissue.[5](#cas14248-bib-0005){ref-type="ref"}, [6](#cas14248-bib-0006){ref-type="ref"}, [7](#cas14248-bib-0007){ref-type="ref"} Moreover, we showed that amplification of the long arm of chromosome 7 (Ch.7q) exists in all regions of a single tumor by undertaking multiregional copy number analysis of tumor tissues in CRC,[8](#cas14248-bib-0008){ref-type="ref"}, [9](#cas14248-bib-0009){ref-type="ref"} suggesting that amplification of Ch.7q is a fundamental and predominant event and that this region harbors oncogenes that affect the tumorigenesis of CRC.

We recently established a screening system using a bioinformatics approach with public datasets to identify candidate oncogenes in CRC. Using this system, we identified phosphoserine phosphatase (*PSPH*) and eIF5‐mimic protein 1 (*5MP1*) as potential oncogenes on Ch.7p in CRC.[10](#cas14248-bib-0010){ref-type="ref"}, [11](#cas14248-bib-0011){ref-type="ref"} Furthermore, we found that their expression was significantly associated with cell cycle progression genes and was an independent poor prognostic factor in patients with CRC. This system enables us to comprehensively search for oncogenes in CRC.

In this study, we aimed to identify novel potential oncogenes on Ch.7q in CRC using this screening system and to clarify the biological and clinical significance of the identified oncogenes in CRC.

2. MATERIALS AND METHODS {#cas14248-sec-0002}
========================

2.1. Selection of candidate genes {#cas14248-sec-0003}
---------------------------------

We obtained RNA sequencing data and DNA copy number data from 615 patients with CRC from The Cancer Genome Atlas (TCGA) from the Broad Institute's Firehose (<http://gdac.broadinstitute.org/runs/stddata__2015_08_21/data/COADREAD/20150821/>). The RNA sequencing data also included expression profiles from 51 paired normal colon samples. Using these data, we extracted candidate genes from 819 genes on Ch.7q that showed positive correlations between DNA copy numbers and mRNA expression levels (cut‐off correlation coefficient, 0.4) (criteria 1) and showed overexpression in tumor tissues compared with normal tissues (more than 2‐fold change) (criteria 2).

2.2. Cell culture {#cas14248-sec-0004}
-----------------

Human CRC cell lines (SW620, COLO205, COLO320, DLD1, HCT116, and LoVo) were purchased from the cell bank at RIKEN BioResource Center (Tsukuba). SW620, COLO205, and DLD1 cells were maintained in RPMI‐1640. COLO320 and HCT116 cells were maintained in DMEM. LoVo cells were maintained in Ham's F12 medium. All media contained 10% FBS with 100 U/mL penicillin and 100 U/mL streptomycin sulfate. All CRC cells were cultured in a humidified 5% CO~2~ incubator at 37°C.

2.3. Total RNA extraction and RT‐quantitative PCR {#cas14248-sec-0005}
-------------------------------------------------

Total RNA from tissues and cell lines was extracted using a modified acid guanidinium thiocyanate‐phenol‐chloroform extraction (AGPC) method with Isogen (Nippon Gene). Reverse transcription was carried out using 8 µg total RNA with M‐MLV reverse transcriptase (Invitrogen), according to the manufacturer's instructions. Quantitative PCR (qPCR) was undertaken using LightCycler FastStart DNA Master SYBR Green I (Roche Diagnostics) as previously described.[12](#cas14248-bib-0012){ref-type="ref"} The expression levels of general transcription factor 2I repeat domain‐containing protein 1 (*GTF2IRD1*) and transforming growth factor β receptor 2 (*TGFβR2*) mRNA were normalized to *GAPDH* mRNA as an internal control. Gene expression was presented as the values relative to the expression level of the cDNA from Human Universal Reference Total RNA (Clontech). The primer sequences for qPCR were as follows: *GTF2IRD1*, forward 5′‐GTGCCAGCCAAAGACAGCAG‐3′ and reverse 5′‐TGGCCATTGCACGAGTGAGA‐3′; *TGFβR2*, forward 5′‐TGGACCCTACTCTGTCTGTGGA‐3′ and reverse 5′‐CCCACTGCATTACAGCGAGAT‐3′; *p21*, forward 5′‐GCGACTGTGATGCGCTAATG‐3′ and reverse 5′‐

GAAGGTAGAGCTTGGGCAGG‐3′; and *GAPDH*, forward, 5′‐TTGGTATCGTGGAAGGACTCTA‐3′ and reverse, 5′‐TGTCATATTTGGCAGGTT‐3′.

2.4. Protein extraction {#cas14248-sec-0006}
-----------------------

For total protein extraction, cells were lysed in lysis buffer (25 mmol/L Tris‐HCl \[pH 7.5\], 150 mmol/L NaCl, 0.2 mmol/L EDTA, 0.1% NP‐40, 5% glycerol, and proteinase inhibitor cocktail).

2.5. Immunohistochemical analysis {#cas14248-sec-0007}
---------------------------------

Immunohistochemistry for GTF2IRD1 in CRC cases with liver metastasis was carried out on formalin‐fixed, paraffin‐embedded tissues as previously described.[13](#cas14248-bib-0013){ref-type="ref"} The primary Ab against GTF2IRD was used at a dilution of 1:100. Rabbit polyclonal Abs to GTF2IRD were purchased from Sigma‐Aldrich. Tumor histology was independently reviewed by an experienced research pathologist (T.T.) at Kyushu University.

2.6. Immunoblotting analysis {#cas14248-sec-0008}
----------------------------

Immunoblotting analysis was carried out as previously described.[14](#cas14248-bib-0014){ref-type="ref"} Briefly, equal amounts of protein (35 μg) were electrophoresed on 4%‐20% Tris‐glycine gels and then electroblotted onto Immobilon‐P Transfer Membranes (Merck Millipore) at 70 V for 4 hours at room temperature. Nonspecific binding sites were blocked with blocking buffer (TBS and 0.1% Tween‐20 with 5% nonfat milk powder) for 1 hour at room temperature, and the blots were incubated with specific primary Abs in blocking buffer (anti‐GTF2IRD1, anti‐TGFβR2, and anti‐phospho‐cyclin‐dependent kinase \[CDK\] 2 \[Tyr15\] Abs at a 1:250 dilution; anti‐phospho‐Smad2, anti‐Smad2, anti‐p21, anti‐phospho retinoblastoma (pRb), anti‐bone morphogenetic protein receptor type 1B (BMPR1b), and anti‐β‐actin Abs at a 1:1000 dilution) at 4°C overnight. After washing, the blots were incubated with an appropriate secondary Ab conjugated with HRP for 1 hour at room temperature. After washing, the detection was undertaken using an ImageQuant LAS 4000 Mini system (GE Healthcare Japan). Rabbit polyclonal Abs targeting GTF2IRD1 were purchased from Atlas Antibodies. Rabbit polyclonal Abs targeting TGFβR2 and mouse mAbs to β‐actin were purchased from Santa Cruz Biotechnology. Rabbit polyclonal Abs targeting phospho‐Smad2, Smad2, p21, and pRb were purchased from Cell Signaling Technology. Rabbit polyclonal Abs targeting BMPR1b were purchased from GeneTex. Rabbit polyclonal Abs targeting phospho‐CDK2 (Tyr15) were purchased from Abcam. Protein concentrations were quantified using Bradford protein assays.

2.7. *GTF2IRD1* siRNA transfection {#cas14248-sec-0009}
----------------------------------

*GTF2IRD1*‐specific siRNA (Silencer Predesigned siRNA: sense CAUCGUCCAUGACAAGUCATT and antisense UGACUUGUCAUGGACGAUGGA) and negative control siRNA (Silencer Negative Control 1 siRNA) were purchased from Ambion. Small interfering RNA oligonucleotides were transfected into SW620 or COLO205 cells using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's instructions.

2.8. Colony formation assay {#cas14248-sec-0010}
---------------------------

Cells (1000 cells/well) were seeded in 6‐well plates. After incubation for 24 hours followed by siRNA transfection, the cells were cultured for an additional 14 days, and the colonies were stained using a Differential Quik Stain Kit (Sysmex) according to the manufacturer's instructions. Visible colonies were photographed using a Chemiluminescence Imaging FUSION SOLO S (VILBER). Colony counts were determined using ImageJ software (NIH).

2.9. Cell proliferation assay {#cas14248-sec-0011}
-----------------------------

Colorectal cancer cell proliferation was assessed using an MTT assay kit (Roche Applied Science) as previously described.[15](#cas14248-bib-0015){ref-type="ref"} After incubation for 24 hours, followed by siRNA transfection, the cells were cultured for an additional 0‐5 days, and the absorbance of the samples was measured.

2.10. Cell cycle assay {#cas14248-sec-0012}
----------------------

Nocodazole (an inhibitor of tubulin assembly; 5 μg/mL) was added 48 hours after siRNA transfection, and the cells were incubated for an additional 16 hours. Cells were harvested, washed with PBS, and fixed in ice‐cold 70% ethanol at −20°C overnight. Samples were then washed with PBS and stained with propidium iodide containing RNase A for 20 minutes at 37°C. Cell cycle distribution was measured by flow cytometry (Sony).

2.11. In vitro invasion assay {#cas14248-sec-0013}
-----------------------------

Cell invasion capacities were assessed using the BD BioCoat Tumor Invasion System, 24 Multiwell (BD Bioscience) as previously described.[15](#cas14248-bib-0015){ref-type="ref"}

2.12. Patients with CRC and collection of clinical samples {#cas14248-sec-0014}
----------------------------------------------------------

Primary CRC samples and paired normal tissues were obtained from 98 patients who underwent surgery at Kyushu University Beppu Hospital and affiliated hospitals from 1992 to 2007. All patients had a histological diagnosis of CRC and were closely followed at 3‐month intervals. The median follow‐up period was 3.0 years. All patients were treated in accordance with the Japanese Society of Cancer of the Colon and Rectum Guidelines for the Treatment of Colorectal Cancer. Written informed consent was obtained from all patients, and the Institutional Review Board of our university approved this study. Sample collection was carried out as previously described.[14](#cas14248-bib-0014){ref-type="ref"} Data on patient age, sex, histology, tumor depth of invasion, lymph node metastasis, lymphatic invasion, venous invasion, liver metastasis, and clinical stage were obtained from clinical and pathological records.

2.13. Cancer Cell Line Encyclopedia data analysis {#cas14248-sec-0015}
-------------------------------------------------

We obtained normalized mRNA expression data and DNA copy number data from 58 available CRC cell lines from the Cancer Cell Line Encyclopedia (CCLE) dataset (<http://www.broadinstitute.org/ccle/home>). Candidate gene mRNA expression and DNA copy number data were extracted from this reference.

2.14. Gene set enrichment analysis {#cas14248-sec-0016}
----------------------------------

The correlations between *GTF2IRD1* expression and previously annotated gene expression signatures were analyzed by applying gene set enrichment analysis (GSEA).[16](#cas14248-bib-0016){ref-type="ref"} We acquired CRC expression profiles from the NCBI's Gene Expression Omnibus database (accession code GSE7963) and analyzed the expression profiles using GSEA. Gene sets of *GTF2IRD1* targets were extracted from C2 curated gene sets in the Broad Institute database (<http://www.broadinstitute.org/gsea/msigdb/collections.jsp>).

2.15. The Cancer Genome Atlas data analysis {#cas14248-sec-0017}
-------------------------------------------

Paired RNA sequencing and survival data of 620 available patients with CRC were obtained from TCGA (<http://cancergenome.nih.gov/>). *GTF2IRD1* mRNA expression, *Smad4* mutation status, and survival data were extracted from this reference.

2.16. Statistical analysis {#cas14248-sec-0018}
--------------------------

For continuous variables, data are expressed as mean ± SD, and statistical analyses were carried out using Student's *t* tests. The degree of linearity was estimated by Pearson's correlation coefficient. Categorical variables were compared using χ^2^ tests or Fisher's exact tests. Overall survival was estimated using the Kaplan‐Meier method, and survival curves were compared using log‐rank tests. Based on the levels of *GTF2IRD1* mRNA expression in our dataset, cases were divided into 2 groups by the minimum *P* value approach, a comprehensive method to find the optimal risk separation cut‐off point in continuous gene expression measurement.[17](#cas14248-bib-0017){ref-type="ref"} Data analyses were undertaken using JMP 12 software (SAS Institute) and R software version 3.1.1 (The R Foundation for Statistical Computing).[18](#cas14248-bib-0018){ref-type="ref"} Clinicopathological factors and clinical stages were classified using the TNM system of classification.

3. RESULTS {#cas14248-sec-0019}
==========

3.1. *GTF2IRD1* is a potential oncogene in CRC {#cas14248-sec-0020}
----------------------------------------------

We identified 8 genes that satisfied the criteria described above. Among the 8 genes, we focused on *GTF2IRD1* (Figure [1](#cas14248-fig-0001){ref-type="fig"}A) because this gene has been reported to promote mammary tumor growth.[19](#cas14248-bib-0019){ref-type="ref"} *GTF2IRD1* mRNA expression in tumor tissues was 4.57‐fold higher than that in normal tissues (*P* \< .0005; Figure [1](#cas14248-fig-0001){ref-type="fig"}B). *GTF2IRD1* mRNA expression and copy numbers were positively correlated in TCGA dataset (*R* = .48, *P* \< .001; Figure [1](#cas14248-fig-0001){ref-type="fig"}C). Consistent with this result, there was a significant positive correlation between *GTF2IRD1* mRNA expression and copy numbers in the CCLE dataset (*R* = .35, *P* \< .05; Figure [1](#cas14248-fig-0001){ref-type="fig"}C). Next, we undertook immunohistochemical analysis to confirm GTF2IRD1 protein expression in CRC tumor cells from our hospital. GTF2IRD1 was stained more intensely in the nuclei and cytoplasm of CRC tumor cells than in those of normal colon cells (Figure [1](#cas14248-fig-0001){ref-type="fig"}D). Notably, GTF2IRD1 showed similar strong staining in tumor cells from liver metastatic lesions from the same patients (Figure [1](#cas14248-fig-0001){ref-type="fig"}D). Moreover, RT‐qPCR analysis also showed that *GTF2IRD1* mRNA expression in tumor tissues was significantly higher than that in paired normal tissues (*P* \< .0005; Figure [1](#cas14248-fig-0001){ref-type="fig"}B). Indeed, *GTF2IRD1* mRNA expression levels in tumor tissues were higher than those in normal tissues in 91.3% of 98 patients with CRC. In addition, GSEA revealed a positive correlation between *GTF2IRD1* mRNA expression and the expression of a gene set involved in cell cycle progression (*P* \< .05; Figure [1](#cas14248-fig-0001){ref-type="fig"}E). These findings suggested that *GTF2IRD1* was a novel oncogene in CRC.

![Identification of candidate oncogenes on chromosome 7q in colorectal cancer (CRC). A, Schematic diagram of the strategy for candidate oncogene selection. Criteria 1: Positive correlations between DNA copy numbers and mRNA expression levels (cut‐off correlation coefficient, 0.4). Criteria 2: Overexpressed in tumor tissues compared with normal tissues (\>2‐fold change). B, Left, *GTF2IRD1* mRNA expression between 615 CRC tissues and 51 normal colon tissues in The Cancer Genome Atlas (TCGA) dataset. Right, *GTF2IRD1* mRNA expression in 98 CRC tissues and paired normal colon tissues in our dataset by RT‐quantitative PCR. \*\*\**P* \< .0005. C, Left, Correlation between GTF2IRD1 copy number and *GTF2IRD1* mRNA expression in TCGA dataset. Right, Correlation between GTF2IRD1 copy number and *GTF2IRD1* mRNA expression in the Cancer Cell Line Encyclopedia dataset. *R*, Pearson's correlation coefficient. D, Immunohistochemical staining for GTF2IRD1 in normal colon and tumor tissues (left), and liver metastatic lesion tissues (right) in the same patients. Original magnification, 40× and 200×. E, Gene set enrichment analysis of the expression of *GTF2IRD1* and cell cycle‐related genes using reference gene sets in the CRC dataset. KEGG, Kyoto Encyclopedia of Genes and Genomes; N, normal tissue; NES, Normalized Enrichment Score; T, tumor tissue](CAS-111-343-g001){#cas14248-fig-0001}

3.2. *GTF2IRD1* promotes proliferation of CRC cells {#cas14248-sec-0021}
---------------------------------------------------

The results of GSEA motivated us to investigate whether *GTF2IRD1* regulated cell cycle progression and consequent tumor proliferation. Accordingly, RT‐qPCR analysis was undertaken to quantify *GTF2IRD1* mRNA expression in several CRC cell lines. Endogenous *GTF2IRD1* mRNA expression was higher in SW620 and COLO205 cells (Figure [2](#cas14248-fig-0002){ref-type="fig"}A). Therefore, SW620 and COLO205 cells were selected for subsequent experiments. To examine the biological roles of *GTF2IRD1* in CRC, we carried out knockdown experiments using siRNA. si*GTF2IRD1* induced significant downregulation of *GTF2IRD1* mRNA expression in SW620 and COLO205 cells (Figure [2](#cas14248-fig-0002){ref-type="fig"}B). Immunoblotting analysis confirmed a substantial decrease in GTF2IRD1 protein in si*GTF2IRD1*‐transfected SW620 and COLO205 cells (Figure [2](#cas14248-fig-0002){ref-type="fig"}B).

![Effects of *GTF2IRD1* knockdown on cell proliferation in colorectal cancer (CRC) cells. A, RT‐quantitative PCR (RT‐qPCR) analysis of *GTF2IRD1* mRNA expression in 6 CRC cell lines. B, Left, RT‐qPCR for *GTF2IRD1* mRNA expression in *GTF2IRD1* siRNA‐transfected SW620 and COLO205 cells and control siRNA‐transfected cells. \*\*\**P* \< .0005. Right, Immunoblotting for total protein expression of GTF2IRD1 in *GTF2IRD1* siRNA‐transfected SW620 and COLO205 cells and control siRNA‐transfected cells. C, Left, Colony formation assays. SW620 and COLO205 cells were cultured after *GTF2IRD1* siRNA or control siRNA transfection for 14 d. Right, Total number of colonies. \**P* \< .05, \*\**P* \< .005. D, MTT proliferation assays. Proliferation rates of *GTF2IRD1* siRNA‐transfected SW620 and COLO205 cells were compared with those of control siRNA‐transfected cells (NC). \**P* \< .05, \*\**P* \< .005, \*\*\**P* \< .0005](CAS-111-343-g002){#cas14248-fig-0002}

The effects of *GTF2IRD1* on proliferation in CRC were examined by colony formation assays and MTT assays. GTF2IRD1 knockdown significantly reduced colony formation (Figure [2](#cas14248-fig-0002){ref-type="fig"}C). The MTT assays showed that GTF2IRD1 knockdown significantly inhibited cancer cell proliferation (Figure [2](#cas14248-fig-0002){ref-type="fig"}D). In contrast, GTF2IRD1 knockdown did not affect invasion potential (Figure [S1](#cas14248-sup-0001){ref-type="supplementary-material"}).

3.3. *GTF2IRD1* promoted cell cycle progression in CRC cells {#cas14248-sec-0022}
------------------------------------------------------------

Next, we undertook cell cycle analysis. GTF2IRD1 knockdown significantly decreased the S phase fraction (Figure [3](#cas14248-fig-0003){ref-type="fig"}A). Furthermore, there was a significant increase in the G~1~/S phase fraction in GTF2IRD1 knockdown cells in the presence of nocodazole, which prevents reentry of cells into G~1~ phase (Figure [3](#cas14248-fig-0003){ref-type="fig"}B). Immunoblotting analysis showed a substantial increase in phosphorylation of CDK2 at Tyr15 and decrease in phosphorylation of Rb, indicating G~1~/S arrest, in GTF2IRD1‐knockdown cells (Figure [3](#cas14248-fig-0003){ref-type="fig"}C). Taken together, these data indicated that *GTF2IRD1* promoted cell proliferation by promoting cell cycle progression in CRC.

![Effects of *GTF2IRD1* knockdown on the cell cycle in colorectal cancer cells. A, Cell cycle distributions were analyzed by flow cytometry. \**P* \< .05, \*\**P* \< .005. B, Cell cycle distributions in the presence of nocodazole were analyzed by flow cytometry. \*\*\**P* \< .0005. C, Immunoblotting for phospho‐cyclin‐dependent kinase 2 (CDK2) (Tyr15) and pRb in *GTF2IRD1* siRNA‐transfected SW620 and COLO205 cells and control siRNA‐transfected cells (NC)](CAS-111-343-g003){#cas14248-fig-0003}

3.4. *GTF2IRD1* downregulates TGFβR2 {#cas14248-sec-0023}
------------------------------------

Expression of *TGFβR2*, a well‐known tumor suppressor gene in CRC, is downregulated by *GTF2IRD1* in mouse embryonic fibroblasts*.* [20](#cas14248-bib-0020){ref-type="ref"}, [21](#cas14248-bib-0021){ref-type="ref"} We initially evaluated the expression of this gene using si*GTF2IRD1*‐transfected SW620 and COLO205 cells. *TGFβR2* mRNA and protein expression levels were significantly higher in si*GTF2IRD1*‐transfected cells than in mock‐transfected cells (Figure [4](#cas14248-fig-0004){ref-type="fig"}A,B). To further test whether *TGFβR2* was a downstream target of *GTF2IRD1*, we measured phospho‐Smad2 levels in GTF2IRD1‐knockdown cells. Immunoblotting analysis showed that phospho‐Smad2 levels were significantly higher in s*iGTF2IRD1*‐transfected cells. Furthermore, there was a strong increase in *p21* mRNA and protein expression (Figure [4](#cas14248-fig-0004){ref-type="fig"}A,B), which is upregulated by activation of TGFβ. These data indicated that GTF2IRD1 downregulated membrane TGFβR2 levels, resulting in reduced TGFβ activity.

![*GTF2IRD1* downregulated the *TGFβR2* gene in colorectal cancer (CRC) cells. A, RT‐quantitative PCR for *TGFβR2* and *p21* mRNA expression in *GTF2IRD1* siRNA‐transfected SW620 and COLO205 cells and control siRNA‐transfected cells (NC). \*\*\**P* \< .0005. B, Immunoblotting for TGFβR2, BMPR1b, phospho‐SMAD2, SMAD2, and p21 protein expression in *GTF2IRD1* siRNA‐transfected SW620 and COLO205 cells and control siRNA‐transfected cells. C, Overall survival rate in patients with CRC according to *GTF2IRD1* mRNA expression in tumor tissues in our dataset. D, Schema indicating that overexpression of GTF2IRD1 promotes cell cycle progression and tumor proliferation](CAS-111-343-g004){#cas14248-fig-0004}

Bone morphogenetic protein (BMP) is a member of the TGFβ superfamily, and *BMPR1b* is a BMP signal receptor. It is well known that TGFβ and BMP signals play an opposing role in kidney disease[22](#cas14248-bib-0022){ref-type="ref"} and bone formation.[23](#cas14248-bib-0023){ref-type="ref"} These motivated us to assess the expression of BMPR1b by GTF2IRD1‐knockdown experiments. Levels of BMPR1b expression were significantly lower in si*GTF2IRD1*‐transfected cells than in mock‐transfected cells (Figure [4](#cas14248-fig-0004){ref-type="fig"}B). This result suggested that GTF2IRD1 upregulated membrane BMPR1b levels.

3.5. *GTF2IRD1* promotes proliferation of *Smad4*‐mutated CRC cells {#cas14248-sec-0024}
-------------------------------------------------------------------

It is well known that the Smad signaling pathway is composed of the TGFβR2, TGFβR1, and Smad proteins. The cytoplasmic Smad2 and Smad3 proteins are phosphorylated by TGFβ signal through TGFβR2 and TGFβR1, which allows them to form a heteromeric complex with Smad4. This Smad complex is translocated into the nucleus and activates gene transcription, including *p21*. Our experimental data showed that GTF2IRD1 downregulated TGFβR2 expression, resulting in the downregulation of phospho‐Smad2 and p21 expression. However, SW620 and COLO205 harbor loss of function mutation of *Smad4*,[24](#cas14248-bib-0024){ref-type="ref"} indicating that the TGFβ signal pathway is inactivated in these cells. Thus, we undertook the cell proliferation assay and immunoblotting analysis using *Smad4*‐wild CRC cells, COLO320, whose endogenous *GTF2IRD1* mRNA expression was near to SW620 and COLO205 cells (Figure [2](#cas14248-fig-0002){ref-type="fig"}A). Unexpectedly, GTF2IRD1 knockdown did not upregulate colony formation (Figure [S2](#cas14248-sup-0002){ref-type="supplementary-material"}A). The MTT assays showed that GTF2IRD1 knockdown did not promote cancer cell proliferation (Figure [S2](#cas14248-sup-0002){ref-type="supplementary-material"}B). The TGFβR2 and phospho‐Smad2 protein expression levels in *Smad4*‐wild cells was higher as well as *Smad4*‐mutated cells, but p21 protein expression levels were lower in si*GTF2IRD1*‐transfected WT cells than in mock‐transfected WT cells (Figure [S2](#cas14248-sup-0002){ref-type="supplementary-material"}c), indicating that GTF2IRD1 downregulated TGFβR2 expression, resulting in reduced p21 expression in *Smad4*‐mutated CRC, but not in *Smad4*‐wild CRC.

3.6. High expression of *GTF2IRD1* mRNA predicts poor prognosis in CRC patients {#cas14248-sec-0025}
-------------------------------------------------------------------------------

Because our experimental data suggested that *GTF2IRD1* was associated with tumor aggressiveness in CRC, we assessed the prognostic and clinical significance of *GTF2IRD1* mRNA expression in CRC. First, we evaluated the survival rates according to *GTF2IRD1* mRNA expression in patients with CRC. The overall survival rate in patients in the high *GTF2IRD1* mRNA expression group was significantly lower than that in patients in the low expression group in our dataset (*P* \< .0005; Figure [4](#cas14248-fig-0004){ref-type="fig"}C). In the univariate analysis, poor histology, higher T factor (≥SE), lymph node metastasis, lymphovascular invasion, liver metastasis, and high *GTF2IRD1* mRNA expression were significantly associated with a lower overall survival rate (Table [1](#cas14248-tbl-0001){ref-type="table"}). The multivariate analysis indicated that liver metastasis (*P* \< .05) and high *GTF2IRD1* mRNA expression (*P* \< .05) were independent poor prognostic factors in CRC (Table [1](#cas14248-tbl-0001){ref-type="table"}). Also, the survival rates according to *Smad4* mutation status in patients with CRC were examined using TCGA dataset because our experimental data suggested that *GTF2IRD1* showed malignant potential in *Smad4*‐mutated CRC. As expected, the overall survival rate in patients in the high *GTF2IRD1* mRNA expression group was significantly lower than that in patients in the low expression group in *Smad4*‐mutated CRC cases (Figure [S3](#cas14248-sup-0003){ref-type="supplementary-material"}A). In *Smad4*‐wild CRC cases, there was no significant difference in the overall survival rate between high and low *GTF2IRD1* mRNA expression group (Figure [S3](#cas14248-sup-0003){ref-type="supplementary-material"}B). These results imply that GTF2IRD1 acts as an oncogene in the *Smad4*‐mutated CRC case, but not in the *Smad4*‐wild CRC case.

###### 

Univariate and multivariate analysis of clinicopathological factors affecting overall survival rate in colorectal cancer patients

  Factor                                   Univariate analysis   Multivariate analysis                                                                          
  ---------------------------------------- --------------------- ----------------------- ------------------------------------------------ ------- ------------- ----------------------------------------------
  Age, \>65/≤65 years                      1.853                 0.843‐4.178             .124                                             --      --            --
  Sex, male/female                         2.027                 0.856‐5.568             .112                                             --      --            --
  Histology grade: well, moderate/others   0.188                 0.071‐0.651             .012[\*](#cas14248-note-0002){ref-type="fn"}     0.275   0.091‐1.059   .059
  T factor, ≤SS/≥SE                        0.193                 0.078‐0.438             \<.001[\*](#cas14248-note-0002){ref-type="fn"}   0.512   0.181‐1.389   .189
  Lymph node metastasis, absent/present    0.189                 0.069‐0.449             \<.001[\*](#cas14248-note-0002){ref-type="fn"}   0.581   0.187‐1.669   .314
  Lymphatic invasion, absent/present       0.349                 0.154‐0.768             .009[\*](#cas14248-note-0002){ref-type="fn"}     0.633   0.235‐1.703   .362
  Venous invasion, absent/present          0.225                 0.101‐0.534             .001[\*](#cas14248-note-0002){ref-type="fn"}     0.392   0.144‐1.072   .068
  Liver metastasis, absent/present         0.091                 0.041‐0.219             \<.001[\*](#cas14248-note-0002){ref-type="fn"}   0.229   0.074‐0.691   .009[\*](#cas14248-note-0002){ref-type="fn"}
  *GTF2IRD1* mRNA expression, low/high     0.269                 0.089‐0.664             .003[\*](#cas14248-note-0002){ref-type="fn"}     0.336   0.103‐0.914   .032[\*](#cas14248-note-0002){ref-type="fn"}

Abbreviations: CI, confidence interval; RR, relative risk; SE, serosa; SS, subserosa.

Statistically significant.

John Wiley & Sons, Ltd

3.7. Clinicopathological significance of *GTF2IRD1* mRNA expression in CRC {#cas14248-sec-0026}
--------------------------------------------------------------------------

Next, we examined the association between *GTF2IRD1* mRNA expression and clinicopathological factors in patients with CRC from our hospital (Table [2](#cas14248-tbl-0002){ref-type="table"}). The high *GTF2IRD1* mRNA expression group (n = 53) had a higher frequency of liver metastasis (*P* \< .05) compared with the low expression group (n = 45), suggesting that CRC cells with high expression of GTF2IRD1 should grow faster than with the low expression at metastatic regions, including liver, resulting in early clinical detection of metastasis of GTF2IRD1‐high expressed CRC cells because GTF2IRD1 can facilitate cell proliferation of CRC. There were no significant associations between *GTF2IRD1* mRNA expression and age, sex, poor histology, depth of invasion, lymph node metastasis, lymphatic invasion, venous invasion, or clinical stage.

###### 

Correlation between *GTF2IRD1* mRNA expression of tumor tissues and clinicopathological factors in colorectal cancer

  Factors                 Low (n = 45)   High (n = 53)   *P* value
  ----------------------- -------------- --------------- ----------------------------------------------
  Age (years)                                            
  \<65                    16 (35.6)      24 (45.3)       .329
  ≥65                     29 (64.4)      29 (54.7)       
  Sex                                                    
  Male                    32 (71.1)      31 (58.5)       .194
  Female                  13 (28.9)      22 (41.5)       
  Histology                                              
  Well/moderate           42 (93.3)      49 (92.4)       .866
  Others                  3 (6.7)        4 (7.6)         
  Depth of invasion                                      
  ≤SS                     28 (62.2)      32 (60.4)       .852
  ≥SE                     17 (37.8)      21 (39.6)       
  Lymph node metastasis                                  
  Absent                  29 (64.4)      27 (50.9)       .178
  Present                 16 (35.6)      26 (49.1)       
  Lymphatic invasion                                     
  Absent                  30 (66.7)      31 (58.5)       .405
  Present                 15 (33.3)      22 (41.5)       
  Venous invasion                                        
  Absent                  38 (84.4)      43 (81.1)       .666
  Present                 7 (15.6)       10 (18.9)       
  Liver metastasis                                       
  Absent                  44 (97.8)      44 (83.0)       .016[\*](#cas14248-note-0004){ref-type="fn"}
  Present                 1 (2.2)        9 (17.0)        
  UICC TNM stage                                         
  Ⅰ, Ⅱ                    27 (60.0)      25 (47.2)       .205
  Ⅲ, Ⅳ                    18 (40.0)      28 (52.8)       

Abbreviations: SE, serosa; SS, subserosa.

Statistically significant.
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4. DISCUSSION {#cas14248-sec-0027}
=============

In this study, we identified *GTF2IRD1* as a driver gene on Ch.7q of CRC using our bioinformatics approach and determined the biological and clinical significance of *GTF2IRD1* expression in CRC. To the best of our knowledge, this is the first study to provide evidence that *GTF2IRD1* might act as a novel oncogene in CRC.

*GTF2IRD1* is a member of the *GTF2I* gene family, which encodes a set of multifunctional transcription factors. *GTF2IRD1* is located in the Williams‐Beuren syndrome critical region 7q11.23.[25](#cas14248-bib-0025){ref-type="ref"}, [26](#cas14248-bib-0026){ref-type="ref"} This syndrome is a genetic disorder associated with multiple systemic abnormalities, including craniofacial dysmorphology and several symptoms, such as hypertension and anxiety.[27](#cas14248-bib-0027){ref-type="ref"} Additional studies have reported that there is a positive correlation between the expression of *GTF2IRD1* and that of cell cycle progression‐related genes and genes involved in the noncanonical Wnt‐calcium pathway, which is known to modulate migration.[28](#cas14248-bib-0028){ref-type="ref"}, [29](#cas14248-bib-0029){ref-type="ref"} Consistent with these data, our GSEA revealed that *GTF2IRD1* expression in CRC was positively correlated with cell cycle‐related gene sets, and in vitro analysis showed that *GTF2IRD1* promoted cell cycle progression and consequently accelerated cell proliferation.

Our clinical study showed that *GTF2IRD1* was overexpressed due to copy number amplification at Ch.7q in CRC. The expression of *GTF2IRD1* was positively associated with the malignant pathological phenotype. Furthermore, high expression of *GTF2IRD1* was an independent poor prognostic factor in CRC. Huo et al revealed that high *GTF2IRD1* expression correlated with poor overall survival in patients with breast cancer, lung cancer, and ovarian cancer.[19](#cas14248-bib-0019){ref-type="ref"} These clinical findings strongly supported that *GTF2IRD1* is a tumor‐promoting oncogene in human cancers, including CRC. Moreover, high *GTF2IRD1* expression could be a novel biomarker of poor prognosis in patients with CRC.

Next, we assessed the mechanisms through which *GTF2IRD1* promoted CRC progression. We found that GTF2IRD1 downregulated TGFβR2 expression, resulting in reduced TGFβ activity in *Smad4*‐mutated CRC (Figure [4](#cas14248-fig-0004){ref-type="fig"}D). Our schema was strongly supported by the fact that suppression of TGFβ activity accelerated cell cycle progression and consequent cell proliferation.[30](#cas14248-bib-0030){ref-type="ref"}, [31](#cas14248-bib-0031){ref-type="ref"} Mutational inactivation of *TGFβR2* occurs in approximately 30% of CRCs and promotes the formation of CRC by inhibiting the tumor‐suppressor activity of the TGFβ signaling pathway.[21](#cas14248-bib-0021){ref-type="ref"}, [32](#cas14248-bib-0032){ref-type="ref"} In a recent paper, *GTF2IRD1* was reported to repress obesity‐associated adipose tissue fibrosis and improve systemic glucose homeostasis by suppressing the TGFβ signaling pathway.[33](#cas14248-bib-0033){ref-type="ref"}

Loss of chromosome 18q21 including *Smad4* has been detected in up to 60% of CRC, and *Smad4* was reported to harbor loss of function mutation frequently in CRC,[34](#cas14248-bib-0034){ref-type="ref"}, [35](#cas14248-bib-0035){ref-type="ref"} suggesting that *Smad4* is dysfunctional in the majority of CRC. Ijichi et al reported that p21 was upregulated through Smad2/3‐dependent transcriptional activation through a *Smad4*‐independent manner in Smad4‐null pancreatic cancer cells.[36](#cas14248-bib-0036){ref-type="ref"} This report suggested a novel mechanism of p21 regulation that Smad4 is not involved. In our study, p21 expression was downregulated in *Smad4*‐mutated CRC cells, but not in *Smad4*‐wild CRC cells, suggesting that *GTF2IRD1* acts as an oncogene possibly in a *Smad4*‐independent manner in *Smad4*‐mutated CRC cases, but not in *Smad4*‐wild CRC cases. Survival analysis according to *Smad4* mutation status supported our hypothesis described above. Our results and the reports suggested that downregulation of *TGFβR2* could be an important pathway in *Smad4*‐mutated CRC formation and progression, but not in *Smad4*‐wild CRC, resulting in the difference of malignant phenotype between *Smad4*‐mutated and *Smad4*‐wild CRC. Further studies will be required to confirm this.

Recently, some reports have focused on the cross‐talk between TGFβ signal and the BMP signaling pathway in the progression of cancers. BMP7 attenuates TGFβ‐mediated tumor suppression in proliferation or invasion in prostate cancer or breast cancer respectively.[37](#cas14248-bib-0037){ref-type="ref"}, [38](#cas14248-bib-0038){ref-type="ref"} In our study, GTF2IRD1 downregulated TGFβR2, but upregulated BMPR1b expression in CRC cells, suggesting that the upregulation of BMPR1b by GTF2IRD1 might indirectly decrease TGFβR2 expression, resulting in suppression of TGFβ signal (Figure [4](#cas14248-fig-0004){ref-type="fig"}D).

Some limitations exist in this study. First, only COLO320 was available as *Smad4*‐wild CRC cells for in vitro analysis. Second, we could not identify the novel signal mediator regulating *p21* instead of *Smad4*. Further in vitro and in vivo experiments are required to clarify these mechanisms.

In summary, our study identified *GTF2IRD1* as a novel oncogene on Ch.7q and showed that GTF2IRD1 promoted cell cycle progression by downregulation of *TGFβR2* in CRC*.* Furthermore, because overexpression of *GTF2IRD1* due to copy number amplification of Ch.7q is considered to be a universal driver event present in all CRC cells, *GTF2IRD1* could be a therapeutic target to overcome ITH in patients with CRC.
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